Context Therapeutics Inc.

01/31/2023 | Press release | Distributed by Public on 01/31/2023 06:39

Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast[...]